Abivax (ABVX) Income towards Parent Company (2022 - 2026)
Abivax's (ABVX) quarterly Income towards Parent Company came in at -$56.7 million in Q1 2026, down 3.01% year-on-year from -$58.5 million in Q1 2025, and up 40.52% quarter-over-quarter from -$95.4 million in Q4 2025.
Abivax (ABVX) Income towards Parent Company (2022 - 2026) Analysis & Trends
Abivax's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$56.7 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 3.01% year-over-year to -$56.7 million in Q1 2026; TTM through Mar 2026 was -$386.2 million, a 93.58% decrease from a year earlier, with the FY2025 full-year figure at -$398.0 million, down 108.72% from the prior year.
- Income towards Parent Company improved to -$56.7 million in Q1 2026 per ABVX's latest filing, from -$95.4 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$41.8 million in Q2 2024 and bottomed at -$179.3 million in Q3 2025.
- The 5-year median for Income towards Parent Company is -$56.7 million (2026), against an average of -$76.0 million.
- Across the five-year window, Income towards Parent Company jumped 69.33% in 2024 and slumped 195.6% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$66.1 million in 2022, then tumbled by 107.34% to -$137.1 million in 2023, then soared by 69.33% to -$42.0 million in 2024, then sank by 126.96% to -$95.4 million in 2025, then soared by 40.52% to -$56.7 million in 2026.
- Per Business Quant, the three latest ABVX Income towards Parent Company figures stand at -$56.7 million (Q1 2026), -$95.4 million (Q4 2025), and -$179.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.74 Mn |
| Dec 31, 2025 | -95.40 Mn |
| Sep 30, 2025 | -179.28 Mn |
| Jun 30, 2025 | -54.80 Mn |
| Mar 31, 2025 | -55.09 Mn |
| Dec 31, 2024 | -42.03 Mn |
| Sep 30, 2024 | -60.65 Mn |
| Jun 30, 2024 | -41.75 Mn |
| Mar 31, 2024 | -46.57 Mn |
| Dec 31, 2023 | -137.07 Mn |
| Dec 31, 2022 | -66.11 Mn |